California Group

Creating a California Cancer Megafund: The Caltech/MIT BioFinance Working Group

Caltech and the MIT Laboratory for Financial Engineering jointly sponsored an invitation-only meeting at Caltech on April 29, 2015 to explore new business models and financial vehicles for raising and deploying funds for the commercialization of new cancer therapeutics (new discoveries to clinically proven drugs) in a scalable and profitable manner. This meeting will brought together a small group of stakeholders from financial institutions, institutional investors, foundations and endowments, and local-area academic medical centers and university research laboratories to engage in active dialogue regarding specific funding needs, potentially new business and legal structures, and new sources of capital to fund such enterprises.

Meeting Agenda
9:00am – 9:30am Registration and Continental Breakfast
9:30am – 10:45am Welcome, Introductions, and Background
Mark Davis (Caltech), Mike Ewens (Caltech), Pablo Legorreta (Royalty Pharma), Andrew W. Lo (MIT), Dick Roll (Caltech)
10:45am – 12:00pm Recent Innovations and Funding Needs
David Baltimore (Caltech), Stephen Forman (City of Hope), Beth Karlan (Cedars-Sinai)
Moderator: Mark Davis (Caltech)
12:00pm – 12:15pm Break
12:15pm – 1:15pm Lunch Discussion: Technology Licensing
Fred Farina (Caltech), Jacob Levin (UC Irvine), Emily Loughran (UCLA), George Megaw (City of Hope)
1:15pm – 1:30pm Break
1:30pm – 2:45pm Potential Business/Financing Structures
Janet Campagna (QS Investors), Gifford Fong (Gifford Fong Associates), Bruce Lehmann (UCSD), Anna Makki (Credit Suisse)
Moderator: Dick Roll (Caltech)
2:45pm – 3:00pm Break
3:00pm – 4:15pm Investor Perspectives
Vineer Bhansali (PIMCO), Neil Kumar (BridgeBio Capital), Alison Li (CalPERS), Tom Philipson (University of Chicago), Rich Wolf (Capital World)
Moderator: Mike Ewens (Caltech)
4:15pm – 5:00pm Wrap-Up and Next Steps